CA-TOPCON-POSITIONING
22.8.2024 01:13:30 CEST | Business Wire | Press release
Topcon Positioning Systems has announced that Ray O’Connor, president and chief executive officer, will retire in September 2025 after over three decades of exceptional leadership. O’Connor will transition to the role of Chairman of the Topcon Positioning Systems Board of Directors effective September 1, 2024, providing guidance and support to the executive leadership team during this important year of transition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240821428653/en/
(Photo: Business Wire)
Succeeding O’Connor as president and CEO is Ivan Di Federico, who currently serves as executive vice president and chief strategy officer for Topcon Positioning Systems. After two decades with the company, Di Federico will assume his new role on September 1, 2024.
“It has been a true privilege to lead Topcon Positioning Systems for the past three decades and witness the incredible growth and evolution of the company,” said Ray O’Connor. “I am immensely proud of what our team has accomplished, and confident that Ivan is the right leader to take the company into the future. His deep technical expertise, strategic vision, and proven track record of driving innovation make him the ideal choice to lead the company through its next chapter of growth and success.”
Under O’Connor’s leadership, Topcon Positioning Systems has experienced dramatic organic growth and expansion into new markets and product lines. During his tenure, he was responsible for numerous key acquisitions, as well as the expansion into GNSS, radios, machine automation, and global positioning software and workflow solutions for the construction and precision agriculture industries.
“Ray has made significant contributions to the global positioning industry through his many patents, inspired by his product vision and application experience — I am honored to succeed him as president and CEO of Topcon Positioning Systems,” said Ivan Di Federico. “Ray has built an exceptional company and a talented team, and I look forward to building upon this strong foundation to drive continued innovation and growth. As we navigate an increasingly complex and rapidly evolving market landscape, I am confident that our strategic focus, operational excellence, and world-class solutions will position the company for continued success.”
In addition to the leadership transition, Topcon also announced that Philip Thach will be promoted to executive vice president (EVP) chief operating officer, and EVP chief financial officer, effective September 1, 2024. Thach joined Topcon in 2018 as CFO and has been instrumental in developing financial controls, strategic planning, and operational efficiencies.
The announcement of these executive leadership changes reflects Topcon’s commitment to a thoughtful and well-planned succession process that will ensure a smooth transition and continued momentum for the company, while maintaining its customer-centric culture and values. With a strong leadership team in place, Topcon is poised to build on its history of innovation and market leadership.
For more information on Topcon Positioning Systems, visit topconpositioning.com.
About Topcon Positioning Systems
Topcon Positioning Systems is an industry-leading designer, manufacturer and distributor of precision measurement and workflow solutions for the global construction, geospatial and agriculture markets. Topcon Positioning Systems is headquartered in Livermore, California, U.S. (topconpositioning.com, LinkedIn, Twitter, Facebook, Instagram). Its European head office is in Zoetermeer, Netherlands. Topcon Corporation (topcon.com), founded in 1932, is traded on the Tokyo Stock Exchange (7732).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240821428653/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom